A person with curly hair wearing blue headphones is lying back on a couch with eyes closed, appearing relaxed.

Depression Kills More People Than Most Cancers. Why Is It Still Treated Like a 1990s Problem?

By David Mahjoubi, MD — Founder, NutraBrain Clinic; President, American Board of Ketamine Physicians

If a cancer killed nearly 50,000 Americans a year, we would have walk-a-thons, awareness ribbons, and billions in research funding aimed at it. We do — for breast cancer, which takes approximately 42,000 American women’s lives annually [1].

Here is the statistic that should stop you: suicide claimed 49,316 American lives in 2023, according to the CDC [2]. That is more than breast cancer. More than prostate cancer. In fact, of the more than twenty major cancer types tracked by the American Cancer Society, only three — lung, colorectal, and pancreatic — are projected to claim more American lives per year than suicide does [3]. And suicide is only the most visible tip of depression’s death toll.

Yet the standard treatment playbook for depression has barely changed since the Clinton administration. This post lays out what the research actually shows — about how lethal depression is, how often standard treatment fails, and why the field has been slow to adopt what works faster.

Depression’s Death Toll Isn’t Just Suicide

Depression is not listed as a cause of death on death certificates, which is part of why it stays invisible. But the epidemiological data are unambiguous.

A meta-analysis of 25 studies covering more than 106,000 individuals found that people with depression have a 1.8 times higher risk of death from all causes compared to non-depressed individuals — and notably, most of that excess death comes from natural causes like cardiovascular disease, not suicide [4]. A 20-year Danish population cohort of 126,573 people diagnosed with depression found life expectancy reduced by roughly 14 years in men and 10 years in women [5]. A 2025 large-scale meta-analysis in World Psychiatry confirmed elevated all-cause mortality across hundreds of studies, while appropriately noting that some of the excess risk reflects co-occurring health factors [6] — an honest caveat, and one that doesn’t rescue the overall picture.

For perspective: the reductions in life expectancy associated with severe depression are comparable to those of smoking or major chronic diseases [6]. Meanwhile, suicide is the second leading cause of death among Americans aged 10–34 [2].

Globally, the World Health Organization estimates that 280 million people live with depression, and it ranks as a leading cause of disability worldwide [7]. Mental health receives less than 2% of global health spending [8].

The 1990s Playbook — and Its Documented Failure Rate

The SSRI era began with fluoxetine’s approval in 1987. Nearly four decades later, the default treatment sequence — try an SSRI, wait four to six weeks, adjust, wait again — is largely unchanged.

We know precisely how well that sequence works, because the NIH funded the largest real-world depression treatment trial ever conducted: STAR*D, with over 4,000 patients. Its findings [9, 10]:

  • Roughly one-third of patients achieved remission on their first antidepressant (the original analysis reported ~37%; a 2023 reanalysis using the original protocol’s criteria put it at 25.5% [10]).
  • With each subsequent medication step, remission rates fell — down to roughly 10% by the fourth attempt [10].
  • Even among patients who eventually remitted, relapse within a year was common.

That means for the majority of patients, the first medication doesn’t produce remission — and every additional failed trial costs six or more weeks of a patient’s life while their mortality risk, job, and relationships hang in the balance. An estimated one-third of treated patients go on to meet criteria for treatment-resistant depression [9].

None of this is an argument against antidepressants, which help millions of people. It is an argument against treating a six-week trial-and-error loop as the only option — in 2026 — for a disease this lethal.

The Science Has Moved. Practice Hasn’t Caught Up.

In 2006, Zarate and colleagues at the National Institute of Mental Health published a randomized, placebo-controlled trial showing that a single ketamine infusion produced antidepressant effects within hours in patients with treatment-resistant depression [11]. It was a landmark: the first strong evidence that depression could respond in hours rather than weeks, through a mechanism (NMDA-receptor modulation and downstream neuroplasticity) entirely different from serotonin-based drugs.

The evidence base has grown steadily since. In 2019, the FDA approved esketamine nasal spray for treatment-resistant depression — the first antidepressant with a genuinely new mechanism of action in decades — after randomized controlled trials (the TRANSFORM and SUSTAIN programs) showed greater symptom reduction and remission versus placebo when added to an oral antidepressant [12]. Randomized trials and meta-analyses of racemic ketamine, including newer oral and extended-release formulations, continue to report rapid reductions in depressive symptoms in treatment-resistant patients [13].

To be precise, because precision matters: racemic ketamine for depression is prescribed off-label, its effects require ongoing treatment or maintenance to sustain, and it is not appropriate for everyone — including patients with active psychosis or uncontrolled substance use disorders. Appropriate screening, physician oversight, and continued psychiatric care are essential. But “requires medical supervision” is a very different problem than “takes six weeks to find out it didn’t work.”

Why the Lag?


If rapid-acting treatments exist and the mortality data are this stark, why does the default remain unchanged? Several reasons show up consistently in the literature: mental health’s chronic underfunding relative to disease burden [8], stigma that suppresses both patient demand and institutional urgency, a reimbursement system built around monthly medication management rather than outcomes, and understandable clinical conservatism about newer agents.

All are real. None of them justify telling a patient with a disease that shortens life expectancy by a decade that their only option is the same sequence of medications we offered in 1996.

The Bottom Line

Depression is a lethal illness — measurably deadlier, in terms of American lives lost each year to suicide alone, than most individual cancer types [2, 3]. Standard treatment fails to produce remission in most patients on the first try [9, 10]. And rapid-acting, evidence-based options now exist, backed by randomized controlled trials and an FDA approval [11, 12].

Patients deserve to know all of that. If you or someone you love has depression that hasn’t responded to traditional treatment, ask more of the system — starting with a conversation with a physician who knows the full range of current options.

NutraBrain Clinic provides physician-led, at-home ketamine therapy for depression, anxiety, PTSD, and chronic pain. Call or text (818) 570-1640 or visit nutrabrainclinic.com to learn whether treatment is right for you.

If you are in crisis or having thoughts of suicide, call or text 988 (Suicide & Crisis Lifeline) or go to your nearest emergency room.

This article is for educational purposes only and does not constitute medical advice. Dr. Mahjoubi recommends patients see a psychiatrist first and maintain psychiatric involvement during ketamine therapy. Individual results vary.

References


David Mahjoubi, MD
www.NutraBrainClinic.com

Posted on behalf of NutraBrain Clinic

Phone: (818) 570-1640